arrow
V

Vered Stearns

johns-hopkins university
H指数:74
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)

EA1211: DIRECT试验:中期FDG-PET/CT预测HER2阳性乳腺癌对新辅助治疗的反应

2025-10-050
PRE
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
BREAST
IF7.9
2025-06-010
OAAI
The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer

霍普金斯诊所的约翰霍普金斯希望: 支持转移性乳腺癌患者的综合需求

2025-01-270
PRE
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108

单药他莫昔芬治疗的转移性乳腺癌患者的CYP2D6活性: ECOG-ACRIN E3108的结果

2024-10-210
PRE
Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial
2024-05-020
PRE
ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial)
2024-05-020
PRE
Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

恩替诺特、nivolumab和ipilimumab治疗晚期HER2-negative乳腺癌的Ib期临床试验

2024-02-147
PRE
Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivors

探索癌症幸存者的骨骼肌线粒体氧化能力,身体功能和心理健康之间的联系

2024-02-011
OAAI
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

TBCRC 039: 术前ruxolitinib联合或不联合紫杉醇治疗三阴性炎性乳腺癌的II期研究

2024-01-314
OAAI
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)
2023-08-313
OA